WCN26-7932 A CASE OF VANISHING BILE DUCT SYNDROME (VBDS) CAUSED BY AVACOPAN (AVA) ADMINISTRAION FOR TREATMENT OF MICROSCOPIC POLYANGIITIS (MPA)

Read full text Summarise with VIRAT
Authors: Michihisa Sugita, 久保田裕哉, Tomomi Ishihara, Sumihisa Ono, Kanyu Miyamoto
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Avacopan (AVA) is widely used in remission induction therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, several cases of vanishing bile duct syndrome (VBDS) after AVA administration were reported, especially in Japan. Therefore, further studies are required to reveal relevance of AVA to VBDS.

Fields of Study & Subjects

Vasculitis and related conditions Gallbladder and Bile Duct Disorders Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106303–106303
Publication date
25 March 2026
Language
EN